EICHORCondition: Glabellar Lines · Sponsor: AbbVie
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL. AGN-151586 is an investigational product being developed for the treatment of GL. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. One group will receive AGN-151586 followed by BOTOX and the other group will receive placebo followed by BOTOX. There is a 1 in 2 chance that participants will be assigned to placebo. Around 80 adult participants with moderate to severe GL will be enrolled in the study in approximately 10 sites around the United States. Participants will receive either AGN-151586 or Placebo administered as 5 intramuscular injections to the glabellar complex on Day 1. Eligible participants may then receive BOTOX injections on Day 30 and will be followed for up to 4 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The Eye Research Foundation /ID# 244430 | Newport Beach, California, United States | — |
| Cosmetic Laser Dermatology /ID# 244425 | San Diego, California, United States | — |
| AboutSkin Research, LLC /ID# 244416 | Greenwood Village, Colorado, United States | — |
| Skin Research Institute LLC /ID# 244424 | Coral Gables, Florida, United States | — |
| Skin and Cancer Associates, LLP /ID# 244415 | Miami, Florida, United States | — |
| DeNova Research /ID# 244421 | Chicago, Illinois, United States | — |
| Advanced Dermatology /ID# 244427 | Lincolnshire, Illinois, United States | — |
| Laser and Skin Surgery Center of Indiana /ID# 244423 | Indianapolis, Indiana, United States | — |
| Bellaire Dermatology Associates /ID# 244428 | Bellaire, Texas, United States | — |
| Premier Clinical Research /ID# 244429 | Spokane, Washington, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05496335